← All trials
NCT05504395
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 14, 2022
- Primary completion
- Nov 30, 2022
- Completion date
- Jan 15, 2023
- First posted
- Aug 17, 2022
- Last posted
- Dec 7, 2022
- Enrollment
- 14
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ConSynance TherapeuticsLead sponsor
- Vanderbilt UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.